Department of Urology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea.
Investig Clin Urol. 2024 Mar;65(2):157-164. doi: 10.4111/icu.20230283.
To examine efficacy and safety of ReMEEX implantation in patients with female stress urinary incontinence (SUI) associated with detrusor underactivity (DU), recurrence, or intrinsic sphincter deficiency (ISD).
Retrospective cohort study included 303 females who underwent ReMEEX system (March 2008 to May 2021). Patients were stratified into three groups by purpose of surgery (SUI with DU, reoperation, and SUI with ISD) and evaluated with following criteria: cure (absence of subjective complaint of leakage and objective leakage in the stress test), improvement (rare leakage subjectively, but satisfaction regardless of stress test), and failure. Primary outcome was success rate of surgery assessed through patient interviews and a stress test. Surgical outcomes and complications were evaluated.
Mean follow-up was 34.4 months (range, 6.0-145.0 months). At the final follow-up visit, 42.9% and 49.2% of patients were cured and improved. Twenty-one point five percent required tension readjustment (mean number, 1.2). The total complication rate was 19.5% (none for grade ≥4). Preoperative Qmax was significantly higher in the ISD group (p<0.001) and preoperative total International Prostate Symptom Score (IPSS) score was significantly higher in the DU group (p=0.044). Moreover, at postoperative 1 year, both total IPSS score and IPSS quality of life score were significantly higher in the DU group (both p=0.001).
The success rate of ReMEEX system was 92.1% at mean follow-up of 34.4 months in female SUI with DU, reoperation, or ISD. It also enabled postoperative readjustment of sling tension, as needed, up to 130 months after surgery.
研究 ReMEEX 植入术治疗女性压力性尿失禁(SUI)合并逼尿肌活动低下(DU)、复发或固有括约肌缺陷(ISD)的疗效和安全性。
本回顾性队列研究纳入了 303 名女性患者,均于 2008 年 3 月至 2021 年 5 月接受 ReMEEX 系统治疗。根据手术目的(DU 合并 SUI、再次手术和 ISD 合并 SUI)将患者分为三组,并采用以下标准进行评估:治愈(无主观漏尿和压力试验中客观漏尿)、改善(主观漏尿罕见,但无论压力试验如何均满意)和失败。主要手术成功率通过患者访谈和压力试验进行评估。评估手术结果和并发症。
平均随访时间为 34.4 个月(范围 6.0-145.0 个月)。在最终随访时,42.9%和 49.2%的患者治愈和改善。21.5%的患者需要调整张力(平均 1.2 次)。总并发症发生率为 19.5%(无≥4 级并发症)。ISD 组术前最大尿流率(Qmax)显著较高(p<0.001),DU 组术前国际前列腺症状评分(IPSS)总分显著较高(p=0.044)。此外,术后 1 年,DU 组的总 IPSS 评分和 IPSS 生活质量评分均显著较高(均 p=0.001)。
在平均随访 34.4 个月时,ReMEEX 系统治疗女性合并 DU、再次手术或 ISD 的 SUI 的成功率为 92.1%。此外,还可以在术后 130 个月按需调整吊带张力。